Nascent Biotech, Inc.
NBIO
$0.0007
-$0.0001-12.50%
OTC PK
| 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | 06/30/2023 | |
|---|---|---|---|---|---|
| Net Income | 26.38% | -149.56% | 75.24% | -53.55% | -4.27% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -112.50% | -84.38% | -44.92% | -39.00% |
| Total Other Non-Cash Items | -55.38% | 242.94% | -121.45% | 569.50% | 71.14% |
| Change in Net Operating Assets | -108.99% | 166.43% | -15.18% | -121.27% | 342.48% |
| Cash from Operations | 7.68% | -6.54% | 3.34% | -109.90% | 57.92% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -100.00% | -- | -- | -- |
| Total Debt Repaid | -- | 100.00% | -200.00% | -- | -- |
| Issuance of Common Stock | -- | 300.00% | -98.26% | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -- | 300.00% | -103.74% | -- | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -29.00% | 33.78% | -138.22% | 711.25% | 57.92% |